Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis.
暂无分享,去创建一个
Varda Rotter | Moshe Oren | V. Rotter | R. Brosh | M. Oren | N. Rivlin | Ran Brosh | Noa Rivlin | Noa Rivlin
[1] R. Ralhan,et al. Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous‐cell carcinoma in India , 2000, International journal of cancer.
[2] J. Bergh,et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] M. Oren,et al. New plays in the p53 theater. , 2011, Current opinion in genetics & development.
[4] P. Jeffrey,et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.
[5] G. Giglia-Mari,et al. TP53 mutations in human skin cancers , 2003, Human mutation.
[6] Toshihide Tsuda,et al. The TP53 gene, tobacco exposure, and lung cancer , 2003, Human mutation.
[7] K. Danenberg,et al. Tumor suppressor gene P53 mutations in human prostate cancer , 1995, The Prostate.
[8] Manuel Serrano,et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity , 2009, Nature.
[9] P. Hainaut,et al. Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. , 2001, Carcinogenesis.
[10] Varda Rotter,et al. When mutants gain new powers: news from the mutant p53 field , 2009, Nature Reviews Cancer.
[11] P. Hainaut,et al. Hepatocellular carcinoma: from gene to public health. , 1997, Journal of the National Cancer Institute.
[12] L. Strong,et al. Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.
[13] J. Fraumeni,et al. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. , 1969, Journal of the National Cancer Institute.
[14] C. Harris,et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.
[15] T. Jacks,et al. The role of p53 in tumour suppression: lessons from mouse models , 1999, Cellular and Molecular Life Sciences CMLS.
[16] H. Ananthaswamy,et al. p53 and the pathogenesis of skin cancer. , 2007, Toxicology and applied pharmacology.
[17] G. Wahl,et al. Linking the p53 tumor suppressor pathway to somatic cell reprogramming , 2009, Nature.
[18] Carl W. Miller,et al. Human p53 gene localized to short arm of chromosome 17 , 1986, Nature.
[19] P. Green,et al. Identification of p53 gene mutations in bladder cancers and urine samples. , 1991, Science.
[20] S. Hirohashi,et al. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. , 1991, Cancer research.
[21] D. Sidransky,et al. Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. , 1994, American journal of surgery.
[22] V. Rotter,et al. Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. , 2005, Cancer research.
[23] W. Deppert,et al. Mutant p53R270H gain of function phenotype in a mouse model for oncogene‐induced mammary carcinogenesis , 2007, International journal of cancer.
[24] V. Rotter,et al. Mutant p53R175H upregulates Twist1 expression and promotes epithelial–mesenchymal transition in immortalized prostate cells , 2011, Cell Death and Differentiation.
[25] J. Milner,et al. Tumor suppressor p53: analysis of wild-type and mutant p53 complexes , 1991, Molecular and cellular biology.
[26] C. Harris,et al. Geographic variation of p53 mutational profile in nonmalignant human liver. , 1994, Science.
[27] L. Strong,et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.
[28] B. Wasylyk,et al. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] R. Hamelin,et al. Correlations between p53‐protein accumulation, serum antibodies and gene mutation in colorectal cancer , 1999, International journal of cancer.
[30] T. Soussi,et al. Serum p53 antibodies as early markers of lung cancer , 1995, Nature Medicine.
[31] T. Soussi,et al. p53 antibodies in the saliva of patients with squamous cell carcinoma of the oral cavity , 1998, International journal of cancer.
[32] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[33] Lubin,et al. p53 antibodies in patients with various types of cancer: assay, identification, and characterization. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] T. Soussi. Analysis of p53 Gene Alterations in Cancer: A Critical View , 2007 .
[35] T. Soussi,et al. p53 Antibodies in the sera of patients with various types of cancer: a review. , 2000, Cancer research.
[36] Michael Dean,et al. Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.
[37] T. Hieken,et al. Predicting the biologic behavior of ductal carcinoma in situ: an analysis of molecular markers. , 2001, Surgery.
[38] M. Oren,et al. mdm2 expression is induced by wild type p53 activity. , 1993, The EMBO journal.
[39] R H Hruban,et al. Progression model for pancreatic cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[40] W. Blattner,et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome , 1990, Nature.
[41] S. Hirohashi,et al. p53 gene mutation spectrum in hepatocellular carcinoma. , 1992, Cancer research.
[42] V. Rotter,et al. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. , 1991, Cancer research.
[43] H. Yamazaki,et al. Involvement of cytochrome P450, glutathione S-transferase, and epoxide hydrolase in the metabolism of aflatoxin B1 and relevance to risk of human liver cancer. , 1996, Environmental health perspectives.
[44] C. Cohen,et al. Immunohistochemical p53 in hepatocellular carcinoma and liver cell dysplasia. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[45] V. Rotter,et al. Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy , 2008, Cell cycle.
[46] T. Uchida,et al. p53 mutations and prognosis in bladder tumors. , 1995, The Journal of urology.
[47] J. Norman,et al. Mutant p53 Drives Invasion by Promoting Integrin Recycling , 2009, Cell.
[48] R. Hruban,et al. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. , 1994, Cancer research.
[49] Shalom Madar,et al. p53-repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation , 2008, Molecular systems biology.
[50] H. Höfler,et al. Genetic Alterations in Presumptive Precursor Lesions of Breast Carcinomas , 2002, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.
[51] p53 regulates epithelial-mesenchymal transition (EMT) and stem cell properties through modulating miRNAs , 2010, Nature Cell Biology.
[52] M. Oren,et al. Mdm2 promotes the rapid degradation of p53 , 1997, Nature.
[53] J. Fraumeni,et al. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? , 1969, Annals of internal medicine.
[54] Y Sawamura,et al. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. , 1999, Neuro-oncology.
[55] M. Olivier,et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.
[56] A. Knudson. Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.
[57] V. Rotter,et al. Review P53 Is Balancing Development, Differentiation and De-differentiation to Assure Cancer Prevention , 2022 .
[58] A. Haese*,et al. Clinical significance of p53 alterations in surgically treated prostate cancers , 2008, Modern Pathology.
[59] T. Iwakuma,et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. , 2008, Genes & development.
[60] M. Olivier,et al. TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. , 2001, Seminars in cancer biology.
[61] V. Rotter,et al. TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance , 2003, Human mutation.
[62] M. Hollstein,et al. p53 and human cancer: the first ten thousand mutations. , 2000, Advances in cancer research.
[63] A. Regev,et al. An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.
[64] D. Evans,et al. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li–Fraumeni syndrome , 1998, Oncogene.
[65] E. Appella,et al. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[66] V. Rotter,et al. p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways. , 2010, Cancer research.
[67] P. Hainaut,et al. 25 years of p53 research , 2005 .
[68] N. Nishishita,et al. Effective generation of iPS cells from CD34+ cord blood cells by inhibition of p53. , 2010, Experimental hematology.
[69] T. Ichisaka,et al. Suppression of induced pluripotent stem cell generation by the p53–p21 pathway , 2009, Nature.
[70] Y. Wang,et al. Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. , 2009, Cancer cell.
[71] B. Vogelstein,et al. A genetic model for colorectal tumorigenesis , 1990, Cell.
[72] P. Laurent-Puig,et al. Circulating free tumor DNA and colorectal cancer. , 2010, Gastroenterologie clinique et biologique.
[73] V. Rotter,et al. Abelson murine leukemia virus-induced tumors elicit antibodies against a host cell protein, P50 , 1980, Journal of virology.
[74] C. Wild,et al. Molecular dosimetry of aflatoxin exposure: contribution to understanding the multifactorial etiopathogenesis of primary hepatocellular carcinoma with particular reference to hepatitis B virus. , 1993, Environmental health perspectives.
[75] M. Blasco,et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming , 2009, Nature.
[76] M. Hollstein,et al. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM , 2007, Nature Cell Biology.
[77] V. Rotter,et al. Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells , 2010, The Journal of experimental medicine.
[78] P. Knoepfler. Deconstructing Stem Cell Tumorigenicity: A Roadmap to Safe Regenerative Medicine , 2009, Stem cells.
[79] H. Shimada,et al. Monitoring of p53 autoantibodies after resection of colorectal cancer: relationship to operative curability. , 2001, The European journal of surgery = Acta chirurgica.
[80] B. Milleron,et al. Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[81] I. Weissman,et al. Stem cells, cancer, and cancer stem cells , 2001, Nature.
[82] V. Rotter,et al. Mutant p53 gain-of-function in cancer. , 2010, Cold Spring Harbor perspectives in biology.
[83] Karen H. Vousden,et al. p53 and its mutants in tumor cell migration and invasion , 2011, The Journal of cell biology.
[84] Xiaolei Yin,et al. Two supporting factors greatly improve the efficiency of human iPSC generation. , 2008, Cell stem cell.
[85] Jacques Ferlay,et al. Estimates of the worldwide incidence of 25 major cancers in 1990 , 1999, International journal of cancer.
[86] D. Evans,et al. Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. , 1999, American journal of human genetics.
[87] J. Milner,et al. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation , 1991, Cell.
[88] M. Ozturk,et al. p53 mutation as a source of aberrant β-catenin accumulation in cancer cells , 2002, Oncogene.
[89] H. Ananthaswamy,et al. P53 protein and pathogenesis of melanoma and nonmelanoma skin cancer. , 2008, Advances in experimental medicine and biology.
[90] R. Carroll,et al. Identification of new polypeptide species (48-55K) immunoprecipitable by antiserum to purified large T antigen and present in SV40-infected and -transformed cells. , 1979, Virology.
[91] D. Louis. The p53 Gene and Protein in Human Brain Tumors , 1994, Journal of neuropathology and experimental neurology.
[92] P. Cerutti,et al. Aflatoxin B1 induces the transversion of G-->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[93] X. Wang,et al. TP53 and liver carcinogenesis , 2003, Human mutation.
[94] T. Soussi,et al. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. , 1994, British Journal of Cancer.
[95] Eytan Domany,et al. The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation , 2005, Molecular systems biology.
[96] Carissa A. Sanchez,et al. Evolution of neoplastic cell lineages in Barrett oesophagus , 1999, Nature Genetics.
[97] P. May,et al. Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum , 1979, Journal of virology.
[98] Ker-Chau Li,et al. p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug , 2009, Nature Cell Biology.
[99] Carlos Caldas,et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.
[100] L. Donehower,et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.
[101] H. Bismuth,et al. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma , 1999, British Journal of Cancer.
[102] V. Rotter,et al. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. , 2000, Cancer research.
[103] D. Pim,et al. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer , 1982, International journal of cancer.
[104] W Atkin,et al. Stool DNA-based colorectal cancer detection: finding the needle in the haystack. , 2001, Journal of the National Cancer Institute.
[105] A. Fersht,et al. Rescuing the function of mutant p53 , 2001, Nature Reviews Cancer.
[106] T. Jacks,et al. Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.
[107] L. Timchenko,et al. Intracellular signaling and hepatocellular carcinoma. , 2011, Seminars in cancer biology.
[108] W. Lutz,et al. Linear dose-response relationship for DNA adducts in rat liver from chronic exposure to aflatoxin B1. , 1990, Carcinogenesis.
[109] A. Børresen-Dale,et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes , 2007, Oncogene.
[110] A. Levine,et al. The first 30 years of p53: growing ever more complex , 2009, Nature Reviews Cancer.
[111] D. Lane,et al. p53, guardian of the genome , 1992, Nature.
[112] P. Shubik,et al. A New, Quantitative, Approach to the Study of the Stages of Chemical Carcinogenesis in the Mouse's Skin , 1947, British Journal of Cancer.
[113] Li-juan Zhang,et al. Changes of serum p53 antibodies and clinical significance of radiotherapy for esophageal squamous cell carcinoma. , 2008, World journal of gastroenterology.
[114] Varda Rotter,et al. Inactivation of the p53 tumor suppressor gene and activation of the Ras oncogene: cooperative events in tumorigenesis. , 2010, Discovery medicine.
[115] Antonio Rosato,et al. A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis , 2009, Cell.
[116] V. Rotter,et al. Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage. , 1993, Oncogene.
[117] H. Brenner,et al. Stool testing for the early detection of pancreatic cancer: rationale and current evidence , 2008, Expert review of molecular diagnostics.
[118] J. Goedert,et al. 249ser TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma , 2005, Oncogene.
[119] V. Rotter,et al. p53 is a regulator of macrophage differentiation , 2004, Cell Death and Differentiation.
[120] V. Rotter,et al. p53 Plays a Role in Mesenchymal Differentiation Programs, in a Cell Fate Dependent Manner , 2008, PloS one.
[121] L. Mao. Genetic alterations as clonal markers for bladder cancer detection in urine , 1996, Journal of cellular biochemistry. Supplement.
[122] M. Hollstein,et al. Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. , 1996, Cancer research.